S&P Futures
4,217.75 +7.75 (+0.18%) Dow Futures
33,330.00 +70.00 (+0.21%) Nasdaq Futures
13,428.00 +36.00 (+0.27%) Russell 2000 Futures
1,973.10 +3.60 (+0.18%) Crude Oil
91.39 -0.54 (-0.59%) Gold
1,787.80 -7.80 (-0.43%)
RedHill Biopharma Ltd. (RDHL)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.9305 |
| Open | 0.9500 |
| Bid | 0.9836 x 2200 |
| Ask | 0.9900 x 1400 |
| Day's Range | 0.9400 - 1.0050 |
| 52 Week Range | 0.6200 - 11.1800 |
| Volume | |
| Avg. Volume | 2,951,819 |
| Market Cap | 69.878M |
| Beta (5Y Monthly) | 1.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for RDHL
Related Research
- Redhill Biopharma Ltd.Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.RatingFair ValueEconomic Moat23 days agoMorningstar
- PR Newswire
RedHill Announces New H. pylori and COVID-19 Data Publication and Presentations at Leading Upcoming Scientific Conferences
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, announced the upcoming presentation of new Talicia® H. pylori eradication data as well as publication and presentation of data from the opaganib and RHB-107 (upamostat) late clinical-stage COVID-19 programs at important medical congresses in July and August, 2022.
- PR Newswire
RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today reported its first quarter 2022 financial results and operational highlights, targeting positive cash from operations1 to start during H2/22 and recent implementation of a comprehensive cost reduction plan, expected to generate operational cost savings of approximately $50 million over the next 18 months.
- PR Newswire
RedHill Biopharma to Host First Quarter 2022 Financial Results and Operational Highlights Webcast on June 23, 2022
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its first quarter 2022 financial results and operational highlights on Thursday, June 23, 2022.
